DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 44.5 in the Healthcare sector.

What is the market capitalisation of Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd has a market capitalisation of approximately ₹1,460 crore.

Fredun Pharmaceuticals Ltd

FREDUNPHARMACEUTICALSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹820

₹2891-40%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹1,460 Cr

P/E Ratio

44.50Expensive

P/B Ratio

5.40

EPS

₹44.07

Book Value

₹488.33

ROE

15.80%Strong

ROCE

19.00%Efficient

Dividend Yield

0.03%

Debt / Equity

0.80Moderate

Face Value

₹10.00

52W High

₹2891.00

52W Low

₹820.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatMedium uncertainty

Fair value estimate

₹517

No recent traded price

BearFair valueBull

₹439₹517₹638

/100

Business quality — Watch the fundamentals

Growth 50Profitability 34Efficiency 55Valuation 37

Plain English

Our view

A steady, established business

How we got there

Fair value methods

Residual income

12% ROE fading to 13% over ~3 yrs, on ₹488 book

₹483

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹638

Analyst target

No analyst coverage

—

Blended fair value₹517

What the numbers say

Investment thesis

Bull case

No standout positives from the current metrics.

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

44.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

15.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.80Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,460 Cr

P/B

5.40

EPS

₹44.07

Div Yield

0.03%

What changed

Recent changes

Promoters+1.11% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 44.5×

Growth

Strong

+32% rev CAGR

Profitability

Healthy

15.8% ROE

Financial health

Comfortable

D/E 0.80

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+32.5%

+36.7%

10Y

+31.3%

Profit

+43.6%

+74.8%

10Y

+41.7%

EPS

+15.8%

+49.0%

10Y

+23.3%

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 75.2% CAGR over last 5 years
Debtor days have improved from 87.9 to 53.2 days.
Promoter holding has increased by 1.51% over last quarter.
Company's median sales growth is 28.6% of last 10 years

Watch-outs

Cons

Promoter holding has decreased over last 3 years: -5.58%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 1.11 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

44%

Promoter

Promoters

44.2%+1.11

Public

44.7%-0.97

FII / FPI

1.1%0.00

DII

2.8%-0.06

Others

7.3%

Total shareholders

8,400-43 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter44.17%

FII1.06%

DII2.83%

Public44.66%

Others7.28%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products[1]